Press Release

NeuroVision has announced completion of a nonexclusive license agreement with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that will significantly expand the companies’ collaboration.

Dr. Black discussing the challenges of Alzheimer’s and some potential solutions, at Google’s Solve for X event.

Google Solve For X

NeuroVision developed a novel retinal imaging technology, which is currently being utilized in a number of clinical trials globally. The test provides clinicians with a simple, objective retinal imaging test that enables detection of amyloid beta plaques and monitoring of patients over time.

Retinal Imaging Test

Animal models, human cadaver studies, and human clinical trials confirm the presence of amyloid beta plaque in the human retina. Ongoing clinical trials demonstrate separation of Alzheimer’s and MCI patients from healthy controls.

Clinical Research

Alzheimer’s begins creating changes in the brain (buildup of amyloid) as many as 20 years before symptoms occur. Early detection is essential.

Alzheimer's Disease

Our Story


NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease.   The company has developed a novel retinal imaging technology, which is currently being utilized in a number of clinical trials globally.

With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases.

Alzheimer’s Facts


Alzheimer’s disease and other dementias will grow each year as the size and proportion of the population aged 65 and older continue to increase. By 2050, the number of people with Alzheimer’s disease is estimated to increase 300% and  reach 131 million.

Today it is the
0th
leading cause of death

Estimated
0 Million
Diagnosed Today
diagnosed every
0
seconds today

Projected Growth
0%
every 20 years
Global Healthcare Costs
$0
Billion today

Projected
0 Million
diagnosed in 2050